July 2025 in “SKIN The Journal of Cutaneous Medicine” Oral minoxidil can help regrow hair lost from antibody-drug conjugate treatment.
34 citations
,
July 2009 in “Journal of Cell Science” ΔNp63α helps control a protein that stops cancer cells from spreading.
16 citations
,
August 2011 in “Annals of Allergy Asthma & Immunology” A woman with severe angioedema improved significantly after treatment with rituximab.
May 2026 in “Journal of Skin and Sexually Transmitted Diseases” Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
1 citations
,
May 2017 in “Journal of Clinical Oncology” Topical calcitriol is safe for preventing hair loss during chemotherapy.
November 2022 in “Journal of Investigative Dermatology” Statins may help treat alopecia areata by reducing harmful immune interactions.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
January 2025 in “Journal of Materials Chemistry B” A new treatment using special microneedles and a nitric oxide-releasing drug could improve hair growth and be more convenient for people with hair loss.
13 citations
,
January 2021 in “The American journal of gastroenterology” Sirolimus effectively reduces lesions and improves quality of life in Blue Rubber Bleb Nevus Syndrome with manageable side effects.
44 citations
,
April 2006 in “Expert opinion on drug safety” Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
January 1994 in “Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics” Both VEPA and ML-Y1 treatments are not effective enough for elderly non-Hodgkin's lymphoma patients.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
2 citations
,
November 2023 in “Acta dermato-venereologica” Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.
16 citations
,
March 2013 in “JAMA Dermatology” A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.
15 citations
,
December 2016 in “Advanced Pharmaceutical Bulletin” The new cream with N-acetyl glucosamine didn't change skin color after 8 weeks.
January 2024 in “Technology in Cancer Research & Treatment” Anti-angiogenic drugs do not worsen COVID-19 severity in lung cancer patients.
17 citations
,
October 2001 in “British Journal of Ophthalmology” Intralesional cidofovir might be a good alternative treatment.
January 2021 in “Mastology” Scalp cooling therapy helped over 80% of women keep at least half their hair during chemotherapy.
October 2023 in “Indian Journal of Skin Allergy” Nab-paclitaxel chemotherapy can rarely cause lupus-like skin issues.
November 2004 in “Oncology Times” Advocacy groups should avoid marketing partnerships that may imply drug endorsements.
41 citations
,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
2 citations
,
October 2018 in “Archives of Dermatological Research” Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.
May 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” Cannabidivarin (CBDV) helps new brain cells grow and develop in a specific brain area through a certain receptor.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” HDAC inhibitors, like Vorinostat and Entinostat, can help regrow hair in alopecia areata.
16 citations
,
January 2025 in “Burns & Trauma” Nanomedicine-based immunotherapy shows promise in improving tissue repair and regeneration.
10 citations
,
June 2024 in “American Journal of Clinical Dermatology” Hedgehog pathway inhibitors for advanced basal cell carcinoma can cause side effects, but managing them helps maintain treatment.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
7 citations
,
December 2016 in “Journal of the American Academy of Dermatology” NKG2D+CD4+ T cells are higher in alopecia areata patients and may be involved in the disease.